Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel hybrid compounds of sclareol and doxorubicin as potential anticancer nanotherapy for glioblastoma

26 Mar 2024

Abstract excerpt

Two novel hybrid compounds, CON1 and CON2, have been developed by combining sclareol (SC) and doxorubicin (DOX) into a single molecular entity. These hybrid compounds have a 1:1 molar ratio of covalently linked SC and DOX. They have demonstrated promising anticancer properties, especially in glioblastoma cells, and have also shown potential in treating multidrug-resistant (MDR) cancer cells that express the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Glioma Diagnosis and Treatment
Share to Nanoplatforms for cancer theranostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38537581
DOI: 10.1016/j.biopha.2024.116496

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel hybrid compounds of sclareol and doxorubicin as potential anticancer nanotherapy for glioblastomaPMID 38537581Read ↗

Nanoarchaeosome-mediated epirubicin delivery induces sustained intracellular stress and suppresses adaptive glioblastoma phentoypesSemantic proximity Read ↗

Nanomedicine Strategies to Overcome Multi-Drug Resistance in Cancer: Innovations in Targeted Delivery, Tumor Microenvironment Modulation and Synergistic TherapiesSemantic proximity Read ↗

EPIC-1042 as a potent PTRF/Cavin1–caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastomaSemantic proximity Read ↗

Overcoming standard-of-care resistance in glioblastoma using nanoparticle-based drug delivery targeting the autophagy pathwaySemantic proximity Read ↗

An overview of targeted cancer therapySemantic proximity Read ↗

Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian CancersSemantic proximity Read ↗

Nanoformulated cell-penetrating survivin mutant and its dual actions.Semantic proximity Read ↗

Coronarin D Induces Apoptotic Cell Death and Cell Cycle Arrest in Human Glioblastoma Cell LineSemantic proximity Read ↗

Surface-engineered dual drug-loaded tumor-targeted liposomal nanoparticles to overcome the therapeutic resistance in glioblastoma multiformeSemantic proximity Read ↗

Ginseng Nanoparticles: A Budding Tool for Cancer TreatmentSemantic proximity Read ↗

Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.Semantic proximity Read ↗

Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing AgentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.